Development of the optimal therapy for obstructive sleep apnea syndrome associated with pulmonary hypertension patients living at high altitude
https://doi.org/10.18093/0869-0189-2016-26-3-379-384
Abstract
The aim of this study was to evaluate prevalence, clinical and functional markers of obstructive sleep apnoea syndrome (OSAS) and to develop the optimal therapy for this disease in patents living at high altitude.
Methods. The study protocol included physical examination, special respiratory questionnaires, 6"min walk test, spirometry, echocardiography, capnography and polysomnography. The trial treatment included CPAP therapy, acetazolamide or combination of both.
Results. A male patient, 62 years of age, with OSAS associated with pulmonary artery hypertension (PAH) was reported in the article according to the study protocol. The combined therapy with CPAP + acetazolamide was the most effective and resulted in improvement in the sleep quality, oxygen saturation, dyspnea, РtcСО2, hypertension, and the heart beat rate.
Conclusion. The combined therapy with CPAP + acetazolamide could be considered as the optimal treatment for patients with OSAS and PAH. OSAS in patients living at high altitude requires further investigations.
About the Author
A. K. Myrzaakhmatova
Academician M.Mirrakhimov National Center of Cardiology and Therapy: 3, Togolok Moldo str., Bishkek, 720040, Kyrgyzstan
Russian Federation
Russian Federation
Researcher at pulmonology and Aller gology Department, Academician M.Mirrakhimov National Center of Cardiology and Therapy; tel.: (+996) 312622763
References
1. Normand H., Vargas E., Bordachar J. et al. Sleep apneas in high altitude residents (3,800 m). Int. J. Sports. Med. 1992; (13, Suppl. 1): 40–42.
2. Yang S.Y., Luo X.H., Feng E.Z. et al. Analysis of prognostic risk factors in the patients with acute exacerbation of chronic corpulmonale and obstructive sleep apnea"hypopnea syndrome in high altitude area. Zhongguo Wei Zhong Bing JiJiu Yi Xue. 2010; 22 (5): 271–274.
3. Kondo T., Ishii H., Tazaki G., Toda M. Exacerbation of obstructive sleep apnea syndrome at altitude 3,850 m.Nichon Kokyuki Gakkai Zasshi. 2008; 46 (12): 1034–1038.
4. Nussbaumer"Ochsner Y., Latshang T.D., Ulrich S.et al. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo"controlled, double"blind trial. Chest. 2012; 141 (1): 131–138.
5. Latshang T.D., Bloch K.E. How to treat patients with obstructive sleep apnea syndrome during an altitude sojourn. High Alt. Med. Biol. 2011; 12 (4): 303–307.
6. Hultgren H.N. High Altitude Medicine. Stanford: Hultgren Publications; 1997: 12.
7. Mirrakhimov M.M., Meymanaliev T.S. High"altitude cardiology. Frunze: «Kyrgyzstan»; 1984 (in Russian).
8. Mirrakhimov M.M, Sooronbaev T.M. Pulmonary disease and high"altitude. In: Chuchalin A.G., ed. Respiratory Medicine. Moscow: GEOTAR"Media; 2007. V. 2: 382–399 (in Russian).
9. Kessler R., Chaouat A., Weitzenblum E. et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur. Respir. J. 1996; 9 (4): 787–794.
10. Bady E., Achkar A., Pascal S. et al. Pulmonary arterial hypertension in patients with sleep apnea syndrome. Thorax. 2000; 55 (11): 934–939.
11. Weaver T.E., Calik M.W., Farabi S.S. et al. Innovative treatments for adults with obstructive sleep apnea. Nat. Sci. Sleep. 2014; 6: 137–147.
12. Fischer R., Lang S.M., Leitl M. et al. Theophylline and acetazolamide reduce sleep"disordered breathing at high altitude. Eur. Respir. J. 2004; 23 (1): 47–52.
13. Latshang T.D., Nussbaumer"Ochsner Y., Henn R.M. et al. Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. JAMA. 2012; 308 (22): 2390–2398.
14. Ng A., Gotsopoulos H., Darendeliler A.M., Cistulli P.A. Oral appliance therapy for obstructive sleep apnea. Treat.Respir. Med. 2005; 4 (6): 409–422.
15. Güvenç T.S., Hüseyinoglu N., Özben S. et al. Right ventricular geometry and mechanics in patients with obstructive sleep apnea living at high altitude. Sleep Breath. 2015; 19: 3539–3540.
16. Kushida C.A., Littner M.R. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 2005; 28 (4): 499–518.
17. Ward M.P., Milledge J.S., West J. High Altitude Medicine and Physiology. New York: Oxford University Press Inc.;2000.
18. Patz D., Spoon M.,Corbin R. et al. The effect of altitude descent on obstructive sleep apnea. Chest. 2006; 130 (6):1744–1750.
19. Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplanta" tion (ISHLT). Eur. Heart J. 2009; 30: 2493–2537.
20. Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219–1263.
Review
For citations:
Myrzaakhmatova A.K. Development of the optimal therapy for obstructive sleep apnea syndrome associated with pulmonary hypertension patients living at high altitude. PULMONOLOGIYA. 2016;26(3):379-384. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-3-379-384
Views:
764
Email this article 